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At the beginning of the 21st century, antimicrobial
resistance is common, has developed against every class
of antimicrobial drug, and appears to be spreading into new
clinical niches. We describe determinants likely to influence
the future epidemiology and health impact of antimicrobial-
resistant infections. Understanding these factors will ulti-
mately optimize preventive strategies for an unpredictable
future.
“Antibiotic therapy, if indiscriminately used, may
turn out to be a medicinal flood that temporarily
cleans and heals, but ultimately destroys life itself.”
Felix Marti-Ibanez, 1955
F
or more than 5 decades, the problem of how to contain
antimicrobial resistance has preoccupied policy mak-
ers and members of the academic community. Nor is this
preoccupation surprising, since antimicrobial resistance
has become a public health concern throughout the world.
Pessimistic viewpoints about the low chances of suc-
cess to stop the development of antimicrobial resistance
have repeatedly been reported (1). The fundamental
predicament is that antimicrobial drugs are a nonrenew-
able resource. Their duration of benefit and availability
appears limited at the biological level, a constraint not seen
with therapies for other disease conditions. As pointed out
by the commentary in this issue of Emerging Infectious
Diseases (2), the emergence of antimicrobial resistance is
unavoidable from an evolutionary perspective. Moreover,
for most microorganisms, it is unlikely that fitness costs of
antimicrobial resistance will reduce their spread and clini-
cal impact, since subsequent evolution commonly results
in the amelioration of these costs (3).
This paradigm, which has been framed from a microbi-
ologic perspective and could be summarized in the slogan
“antibiotic therapy: use it and lose it,” prompts questions
about potential interventions that could slow down the dis-
semination of antimicrobial resistance and reduce its
health impact in the next 2 decades. What will influence
the demand and use of antimicrobial drugs in the near
future? Which obstacles towards more judicious use and
decreased transmission may get circumvented? How much
will healthcare regulation affect antimicrobial resistance
and our ability to control its spread? In short, we need to
complement analysis of molecular biology with an exami-
nation of other determinants that are likely to influence the
future epidemiology and health impact of antimicrobial-
resistant, bacterial infections. That is the purpose of this
article. For space reasons, we will not discuss the problem
of viral, protozoal, or fungal resistance, and the controver-
sial use of antimicrobial drugs in animal growth promo-
tion, but certain analogies may be drawn from the ideas
presented here.
Potential Determinants of the 
Future Dissemination and Control of
Antimicrobial Resistance
Factors that drive uncertainty regarding the future dis-
semination and control of antimicrobial resistance are
numerous and diverse. These determinants can be grouped
into 4 categories (Table 1) (4,5). The first group is related
to the molecular characteristics of pathogens, such as viru-
lence, transmissibility, and survival fitness, which are
issues beyond the scope of this article. Moreover, progress
in microbiologic detection and identification of infectious
pathogens is likely to influence diagnostic uncertainty and
prescribing patterns of antimicrobial drugs. The second
group of determinants is linked to prescribers of antimicro-
bial drugs, physicians, who may change their prescription
patterns. Recent data from different parts of the world
show promise in this area. The third group is related to
characteristics of patient populations and host-related fac-
tors. Not only does this include infection rates and case-
mix characteristics, but also consumer attitudes and global
migration patterns. A fourth group of determinants is
linked to macro-level factors related to the healthcare envi-
ronment. These factors include regulatory policies that
may influence use of antimicrobial drugs, infection control
practices, technologic development, and drug discovery.
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Diagnostic uncertainty is a key driver of drug misuse
and overuse, which can lead to antimicrobial selection
pressure and increased rates of resistant microbes (5). The
risks associated with untreated microbial infection and the
lack of accurate clinical or laboratory prediction methods
result in a low threshold for initiating empirical antimicro-
bial drug therapy, especially if infection could be life-
threatening (6).
In the future, diagnosis of microbial infection may be
improved at several levels, allowing reduction of antimi-
crobial selection pressure. First, new diagnostic tests will
facilitate initiation or withdrawal of antimicrobial therapy
soon after onset of symptoms, especially in the hospital set-
ting. Several new biological markers, such as procalcitonin
and soluble triggering receptors expressed on myeloid
cells, have been proposed to serve either goal (7,8). Second,
molecular diagnostics may increase diagnostic accuracy
and enable more prudent antimicrobial drug use in the
future. Amplification technology with DNA microarrays
and simplified automation opens the potential for rapid test-
ing. Dunne et al. described a scenario in which by the year
2025, sophisticated laboratory platforms with real-time
amplifiers will automatically obtain and analyze clinical
samples and be able to detect any potentially pathogenic
microbe within 30 minutes (9). The threat of bioterrorism
may also foster research about rapid molecular diagnostic
tests that may be used at the bedside. Third, new diagnostic
tools may be available to rapidly distinguish between bac-
terial and viral infections in the ambulatory setting. Fourth,
profound changes will be seen in the techniques used to
perform molecular identification and antimicrobial suscep-
tibility testing. In summary, there are several lines of evi-
dence suggesting that a number of molecular, immuno-
logic, and microbial techniques will change the way   infec-
tious diseases are diagnosed and reduce diagnostic uncer-
tainty in the next 2 decades (10).
Prescribing Antimicrobial Agents
To most clinicians, the immediate risk for the patient
outweighs the long-term disadvantages of liberal use of
antimicrobial drugs. One of the most promising means of
reducing antimicrobial selection pressure without impair-
ing patient safety is cessation of antimicrobial drug thera-
py in patients who do not have a bacterial infection. Great
progress has been made within the last 5 years to shorten
the duration of treatment with antimicrobial agents (11).
Prediction rules designed for the early discontinuation of
antimicrobial agents have been validated by prospective
trials and will further optimize antimicrobial drug use (12).
Although antimicrobial drug policies and guidelines
may not have been of great help in individual decision
making, they may have sensitized the medical community
to the growing problem of antimicrobial drug overuse and
resistance. Consequently, in many industrialized countries,
either the number of antimicrobial agent prescriptions or
the volume of antimicrobial use has decreased over the last
10 years, especially in the ambulatory setting (Table 2)
(13,14). A plateau in worldwide antimicrobial consump-
tion seems to have been reached, leading to a saturated
market. As stated recently by representatives of the phar-
maceutical industry, “The awareness of the relationship
between use and emerging resistance has led to efforts to
decrease, even restrict, antibiotic use, and therefore
decrease the positive influence of resistance on the market
and decrease market potential” (15).
Population Characteristics and 
Technologic Development
Case-mix characteristics and infection rates both inside
and outside the healthcare setting will influence antimicro-
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immunocompromised patients, the growing life-expectan-
cy, and the susceptibility of older persons to infections
could indirectly contribute to greater antimicrobial drug use
and dissemination of resistant microbes. Moreover, infec-
tious diseases are influenced by developments in other areas
of patient care. New technologies and treatments can create
new infectious diseases or eliminate existing ones. For
instance, cancer chemotherapy led to new types of suscep-
tible hosts and infectious disease problems, indirectly
impelling the dissemination of antimicrobial resistance
within hospitals. Key trends in clinical care and biomedical
discovery that are likely to influence antimicrobial resist-
ance are the increased use of medical devices and gene ther-
apies, and better management of chronic diseases such as
diabetes and cancer. These developments will likely reduce
some types of resistance problems and help spawn others.
Global threats such as the next influenza pandemic may
also affect prescribing of antimicrobial drugs by reversing
the trend of decreasing antimicrobial drug consumption
(16). Conversely, climate change may lead to a decrease in
respiratory tract infections and antimicrobial drug use in
the winter months (17).
Travel and Globalization
Globalization and migration into mega-cities has led to
new possibilities of cross-transmission of antimicrobial
resistance (1). Recent events such as the terrorist attack in
Bali, the war in Iraq, and the tsunami in Southeast Asia
have led to the transfer of patients infected with panresis-
tant gram-negative bacteria such as Acinetobacter spp. to
other parts of the world, causing outbreaks and public
health concerns (18). Within the next 2 decades, global
mixing, increased population density, and decreased travel
times will facilitate the spread of a variety of antimicro-
bial-resistant pathogens such as fluoroquinolone-resistant
pneumococci and enteric microbes.
Since antimicrobial resistance is influenced by interna-
tional travel and globalization, resistance may, in turn,
affect how nations respond to each other. Especially as sur-
veillance systems improve in quality, international pres-
sure may be applied to induce change in countries where
antimicrobial agents are abused or where infection control
policies are lax. The situation in antimicrobial resistance
might become comparable to that which exists for other
infectious problems such as mad cow disease: economic
pressure may contribute to compliance and uniformity in
control measures. Nevertheless, approaches to control the
global spread of resistance will remain difficult to imple-
ment and will require intensive surveillance and screening
efforts.
Health Beliefs and Antimicrobial Drug Demand
Although the interplay between health beliefs and
demand of antimicrobial drugs is widely recognized, few,
if any, systematic studies exist about the future influence
of the cultural setting on antimicrobial drug use and relat-
ed resistance rates (19). Social constraints and cultural
views of infectious conditions that require antimicrobial
treatment exert a strong influence on their use, particular-
ly for community-acquired pathogens.
Several countries have recently taken the bold step of
launching national campaigns to educate physicians and
patients about antimicrobial misuse and the threat of resist-
ance (Figure 1). These campaigns show promise in chang-
ing attitudes and behavior, among both the public and
healthcare professionals (20). If repeated regularly, the
campaigns are likely to reduce inappropriate patient
requests for antimicrobial agents, which in conjunction
with physician education models may reduce inappropriate
antimicrobial prescription practices (21). Ultimately, they
may slow the dissemination of certain antimicrobial-resist-
ant pathogens (5). For instance, in several countries, such
as France and Spain, which use a great amount of antimi-
crobial agents, a decrease in pneumococcal resistance rates
among invasive isolates has been noted recently. This coin-
cides with a decrease in antimicrobial drug use after
nationwide campaigns and the introduction of a conjugate
pneumococcal vaccine (22). Nevertheless, uncertainty per-
sists about possible negative outcomes and countermea-
sures taken by the pharmaceutical industry to oppose these
campaigns.
Vaccinology
Modern vaccinology (the development of new vac-
cines) is likely to contribute to the decreased transmission
and impact of antimicrobial-resistant bacteria in the near
future (23). More so than antimicrobial agents, vaccines
have the potential to durably control infectious agents by
blocking their ability to disseminate within a population.
This expectation can be illustrated by the example of the
new pneumococcal conjugate vaccine. Based on encourag-
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mococcal resistance such as Israel, France, Spain, and the
United States, this vaccine will likely reduce the incidence
of invasive disease due to resistant pneumococci (22,24).
Further progress in pneumococcal vaccine development
can be expected from conjugate vaccines that include more
than 7 serotypes (25). Yet uncertainty remains regarding
serotype replacement and the emergence of resistance in
nonvaccine serotypes (25).
Other vaccines to prevent invasive, antimicrobial-
resistant infections will be launched within the next 20
years (23). Potential candidates are vaccines against mul-
tidrug-resistant staphylococci and enterococci, but clinical
studies need to confirm promising preliminary results.
Infection Control in the Healthcare Setting
While the intense selective pressure of antimicrobial
drug use has been an important factor in the emergence of
resistance, the inconsistent application of infection control
guidelines by hospital personnel largely accounts for the
dissemination of resistance in the healthcare setting.
Infection control measures to limit the spread of antimicro-
bial resistance are being increasingly well defined. Despite
the increase in the prevalence of resistance of several
important pathogens, there has been some success in con-
trolling its clinical impact. Several countries have recently
reported a stabilization or decrease in infection rates due to
multidrug-resistant Staphylococcus aureus (26).
The next 20 years will see an increase in infection con-
trol research and interventions to improve patient safety.
Hand hygiene with alcohol-based hand rubs has been
shown to decrease the transmission of resistant organisms
(27). A campaign sponsored by the World Health
Organization in 2005 is promoting its practice throughout
the world. Early screening and isolation of patients carry-
ing resistant organisms also appear to decrease the spread
of resistant microorganisms and may be more widely
implemented (28). Some experts have suggested that mul-
timodal approaches that use a combination of different
measures (for example, aggressive infection control with
active surveillance cultures, hand hygiene, and possibly
antimicrobial control) will effectively slow down and even
halt the increasing trends of healthcare-associated antimi-
crobial resistance (29).
Healthcare Regulation
Antimicrobial use is affected by reimbursement poli-
cies, financial incentives, and healthcare regulation (19).
Forecasting the political and regulatory development in
this area presents a major challenge. There is always a
short-term lack of predictability with regard to political
decision-making after unexpected epidemiologic situa-
tions, such as the bioterrorist attacks in 2001 and severe
acute respiratory syndrome in 2003, which quickly influ-
enced perceived medical needs (30).
Looking at the future impact of healthcare regulation,
many believe that political measures to control antimicro-
bial drug use have only a negligible short-term effect
(1,31). We argue, however, that healthcare regulation will
powerfully influence antimicrobial drug use in the future.
To underline this hypothesis, we give 3 examples from dif-
ferent continents.
Interdiction of Over-the-Counter Sales of
Antimicrobial Agents in Chile 
Self-medication is an important driver of antimicrobial
overuse in low- and middle-income countries. Therefore
since 1999, the Chilean Ministry of Health has strictly
enforced existing laws, which restricted purchase of
antimicrobial agents without a medical prescription. These
regulatory measures had a sustained impact on antimicro-
bial use in the outpatient setting: sales of orally used
antimicrobial agents decreased by 43% from US $45.8
million in 1998 to US $26.1 million in 2002 (Figure 2)
(32).
Restriction of Perioperative Antimicrobial
Prophylaxis in Belgium 
Inadequate and prolonged perioperative antimicrobial
prophylaxis increases resistance to antimicrobial drugs
(33). In 1997, a Royal Decree in Belgium limited reim-
bursement of antimicrobial drug prophylaxis to specific
agents and a 24-hour period after surgery (34). Moreover,
a fixed fee for antimicrobial costs was attributed to each
type of intervention. As shown in Table 3, this regulatory
restriction had a sustained effect on the use of antimicro-
bial prophylaxis in Belgium (34).
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Figure 1. Posters from nationwide educational campaigns against
misuse of antimicrobial drugs.Separation of Dispensing and 
Prescribing in South Korea 
In Europe and North America, separation of antimicro-
bial prescribing and dispensing is a well-established sys-
tem. In contrast, in many Asian countries, healthcare
providers earn a significant proportion of their income
from dispensing drugs, especially broad-spectrum antimi-
crobial agents (35). Consequently, physicians have tradi-
tionally compensated for relatively low medical service
revenue by prescribing a high volume of antimicrobial
agents. In 2000, against the strong opposition of physicians
and the pharmaceutical industry, a new Korean govern-
ment policy prohibited physicians from dispensing drugs
and pharmacists from prescribing drugs (36). This new
policy decreased overall prescribing of antimicrobial
agents and selectively reduced inappropriate prescribing of
them for patients with viral infections (36).
Future Directions
The uncertainty evolving around micro- and macro-
level determinants influencing antimicrobial resistance
makes long-term prediction challenging. Although simula-
tion studies may provide guidance about short-term trends
(37), long-term predictions about the future of antimicro-
bial resistance are fraught with difficulties, as shown by a
look back in history. When the antimicrobial drug era
began, scientists were impressed by the milestones of
antimicrobial agent discovery and issued predictions about
the future of antimicrobial resistance that seem overly opti-
mistic today (38). For instance, in 1952, a famous French
microbiologist anticipated pneumococci, gonococci, and
meningococci would not change their antimicrobial sus-
ceptibility profile in the future (“Pour une espèce qui au
départ était entièrement sensible…, l’espèce sera toujours
aussi sensible. C’est le cas des germes très sensibles à la
pénicilline: gonocoques, pneumocoques, méningoco-
ques”) (39). Yet exactly 40 years later, we were rapidly
progressing towards a “post-antimicrobial era” in which
doctors may become helpless against even common infec-
tions (40).
In the last part of this article, we contemplate the possi-
ble status of antimicrobial resistance in 2025. Although the
direction of a few major trends seems relatively easy, other
factors that drive uncertainty present tremendous forecast-
ing challenges. Therefore, we have developed 2 alternative
scenarios about the future dissemination and control of
antimicrobial resistance. These were extrapolated from the
key determinants discussed earlier. The informed reader of
2025 may apologize for our lack of imagination.
What Will Be the Status of Antimicrobial Resistance 
in 20 Years? 
The Bright Scenario
We will observe a change in prescribing habits and atti-
tudes towards outpatient antimicrobial use, especially for
respiratory infections. Policies and behavior change inter-
ventions contribute to a massive change in social norms
around antimicrobial drug use, similar to what has hap-
pened with tobacco control. Intensive educational cam-
paigns, aimed at optimizing antimicrobial drug use,
combined with immunization programs for infants and
children will lead to reduced spread and clinical impact of
antimicrobial-resistant pneumococci.
Tools from information technology and progress in
microbiology will reduce diagnostic uncertainty and
improve antimicrobial dosing, selection, and treatment
duration. Use of antimicrobial agents will, therefore, con-
tinue to decrease, not only in the outpatient setting, but
also in the inpatient setting.
New therapies will be developed based on probiotic
principles. Technologic advances will enhance the identi-
fication and characterization of the vast microbial
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Figure 2. Number of antimicrobial drug packages sold in the out-
patient setting in Chile, 1988–2002. Package is the term used to
show sales figures of antimicrobial drugs from wholesalers or
pharmacies. It is also used to calculate the number of daily defined
doses for each marketed antimicrobial drug. Data are from
Bavestrello et al (32). Unpublished data from 2001 and 2002 were
provided by A. Cabello Munoz and L. Bavestrello (Viña del Mar,
Chile).diversity colonizing the human body (commensals and
pathogens), which may lead to new probiotic strategies to
prevent infections and reduce antimicrobial selection
pressure.
Data sharing and increased international cooperation
will lead to consistent control measures across different
continents. Asian countries, users of large amounts of
antimicrobial agents and important drivers of resistance
until recently, will change paradigms and introduce mod-
ern infection control concepts and public health policies
that will decrease overuse of antimicrobial agents.
Antimicrobial resistance among important pathogens
will be slowly reversible. Trends in antimicrobial resist-
ance follow an S-shaped curve with a quick ascent, a
plateau and, sometimes, a slow decline. Antimicrobial
resistance in high prevalence countries will be slowly
reduced, especially for several gram-positive microorgan-
isms (1).
Antimicrobial resistance will not have a major impact
on life expectancy in the industrialized world. Deaths from
panresistant infections without any treatment option will
remain rare complications in high-income countries, since
new antimicrobial agents and better use of currently avail-
able antimicrobial drugs will become standard policy.
The Dark Scenario
New resistance mechanisms will emerge and dissemi-
nate. Multiresistant group A streptococci will render peni-
cillin and macrolides useless in the treatment of
pharyngitis. Salmonella spp. infections can no longer be
treated with advanced cephalosporins, fluorquinolones, or
carbapenems.
We will observe raising resistance rates for most
pathogens. Multiresistant Acinetobacter spp., enterococci,
and staphylococci will cause substantial illness and
increased treatment costs in those parts of the world that
have not installed stringent control measures. Healthcare-
associated infections due to vancomycin-resistant entero-
cocci will become endemic in many countries.
Antibacterial-resistant S. aureus will become a massive
public health problem. The scope of staphylococcal
antimicrobial resistance will extend not only to new
antimicrobial agents, but also to more settings. Although
hospitals were once the sole province of methicillin-resist-
ant S. aureus (MRSA), more and more community out-
breaks of MRSA will occur in those persons who lack
traditional risk factors for carriage of MRSA. The preva-
lence of MRSAin the US community will reach 25% with-
in the next decade, with rates 3 times as high in hospitals
(41).
Technological development will not fulfill its promise.
No new antimicrobial classes or treatment strategies have
been developed for gram-negative bacteria, and vaccines
have not been widely effective. Serotype replacement in
pneumococci allowed that organism to escape control.
Fluoroquinolones are no longer effective against a wide
array of infections and have not been replaced by any new
class of orally available antimicrobial agents. New antimi-
crobial drugs with novel mechanisms of action (e.g., bac-
teriophages) have failed in large phase III trials.
Anthrax and pandemic influenza threats have led to
mass prophylaxis, with disastrous consequences in terms
of resistance. Several disasters and pandemics will
increase the use of antimicrobial drugs on a global scale,
leading to emergence and dissemination of resistance.
A continuing flood of consensus conference statements,
position papers, and surveillance network reports will be
issued about the problem of antimicrobial resistance, with-
out any measurable and sustained effect on containment.
Healthcare policy will not introduce stringent control
measures because of a lack of precise estimates of the pub-
lic health impact of antimicrobial resistance and the prior-
ity of other more pressing infectious disease problems such
as HIV, tuberculosis, and malaria.
Conclusion
The high levels of uncertainty and complexity regard-
ing antimicrobial resistance mandate that we build the
capabilities to prepare not only for 1 specific future (fol-
lowing the pessimistic viewpoint of antimicrobial therapy:
use it and lose it), but also across a range of alternative sce-
narios that may be less pessimistic.
Whether the current epidemic of antimicrobial resist-
ance is sustainable or will succumb to current efforts to
limit its spread will be decided by an interaction of factors
related to microorganisms, host, use patterns of antimicro-
bial drugs, and the impact of infection control measures
and technologic development (5). We hope that adding
infection control and prudent use of antimicrobial agents to
new drug development will avert the realization of pes-
simistic predictions about the future of antimicrobial
resistance.
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